# Safety and Efficacy of a Novel Glucagon Formulation in Type 1 Diabetic Patients Following Insulin-induced Hypoglycemia

> **NCT01556594** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 18 (actual)

## Conditions studied

- Hypoglycemia

## Interventions

- **DRUG:** Nasal Glucagon 1 mg
- **DRUG:** Nasal Glucagon 2 mg
- **DRUG:** SC Glucagon
- **DRUG:** Nasal Glucagon 3 mg

## Key facts

- **NCT ID:** NCT01556594
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2012-07
- **Final completion:** 2012-07
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2019-09-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01556594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01556594, "Safety and Efficacy of a Novel Glucagon Formulation in Type 1 Diabetic Patients Following Insulin-induced Hypoglycemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01556594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*